Erlotinib and Sorafenib in Chemonaive Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer
Status:
Unknown status
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
Patients with advanced or metastatic (stage IIIB-IV) non small cell lung cancer who have not
received prior chemotherapy will be treated with erlotinib 150 mg once a day and sorafenib
400 mg twice a day. The objectives of the study are to assess the efficacy and safety of this
combination treatment. Additional exploratory study objectives are correlation of biomarkers
and imaging modalities potentially predictive for response and (progression free) survival.